Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25% on Monday after the company’s experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime.
The drug developer, which went public in January, is one of the many that are eyeing the lucrative market of weight-loss drugs that have been dominated by GLP-1 drugs from Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab.
